Manish Sarkar
7 Aug 2025
A project at the crossroads of multi-omics, behavior and artificial intelligence
MedInsights has announced a long-term collaboration with the Biologie Fonctionnelle et Adaptative (BFA) laboratory at Université Paris Cité, beginning in August 2025. This partnership aims to explore new diagnostic and therapeutic approaches for metabolic and compulsive disorders. The project will leverage MedInsights' Nexus-Rx platform, which uses explainable AI, deep graph learning, and a digital twin model of biological systems to identify new drug targets and predict drug mechanisms. The collaboration focuses on a genetic polymorphism associated with increased vulnerability to metabolic and addictive behaviors, which affects a gene encoding a kinase whose function is currently unknown. The BFA lab has developed experimental models to study the associated behavioral and metabolic phenotypes, providing a unique framework to test the biological efficacy of compounds identified by MedInsights' AI.
According to MedInsights' Founder and CEO, Soham Saha, the Nexus-Rx platform is designed to unlock new therapeutic avenues for millions affected by various cardio-metabolic and neuro-metabolic conditions.
The complete press release can be found in the attached PDF document.